Patients with cervical cancer undergoing interstitial brachytherapy
Conditions
Interventions
Group remimazolam:Sufentanil 0.1 µg/kg + granisetron 3mg+remimazolam [induction: 0.3 mg/kg, maintenance: 0.2-1 mg/kg/h]
Group propofol:Sufentanil 0.1 µg/kg + granisetron 3mg+ propofol [induction 1.5 mg/kg, maintenance: 2-6 mg/kg/h (0-1 µg/kg/min)]
Sponsors
Sichuan Cancer Hospital
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: (1)Histologically confirmed cervical carcinoma candidates for three interstitial brachytherapy sessions (2)BMI 18-30 kg/m^2 (3)ASA class I-II (4) Provision of signed informed consent and willingness to comply with follow-up evaluations.
Exclusion criteria
Exclusion criteria: (1) Patients declining trial participation; (2) History of severe cardiac, cerebral, pulmonary, hepatic, renal, or metabolic diseases; (3) Previous adverse anesthesia recovery; (4) Electrocardiogram (ECG) showing heart rate 180 mmHg and/or diastolic BP >110 mmHg) or hypotension (7 one day pre-procedure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraoperative adverse effects; | — |
Secondary
| Measure | Time frame |
|---|---|
| hypoxemia; hypotension;bradycardia;SpO2;Blood pressure;Heart rate;Operation time;Awakening time;Total sedative drugs;Postoperative adverse effects;Pittsburgh Sleep Quality Index;Athens Insomnia Scale; | — |
Countries
China
Contacts
Public ContactShu Jinjun
Sichuan Cancer Hospital
Outcome results
None listed